SANOFI-ADR (SNY) Stock Fundamental Analysis
NASDAQ:SNY - Nasdaq - US80105N1054 - ADR
SNY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY has a bad growth rate and is valued cheaply. With these ratings, SNY could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
SNY had positive earnings in each of the past 5 years.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 6.07%, SNY belongs to the best of the industry, outperforming 89.78% of the companies in the same industry.
SNY has a better Return On Equity (10.83%) than 89.25% of its industry peers.
Looking at the Return On Invested Capital, with a value of 12.36%, SNY belongs to the top of the industry, outperforming 90.32% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 43.99%.
The 3 year average ROIC (7.23%) for SNY is below the current ROIC(12.36%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROIC | 12.36% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.23%
ROIC(5y)6.72%
1.3 Margins
With an excellent Profit Margin value of 11.06%, SNY belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
In the last couple of years the Profit Margin of SNY has remained more or less at the same level.
SNY has a Operating Margin of 21.92%. This is amongst the best in the industry. SNY outperforms 87.63% of its industry peers.
SNY's Operating Margin has improved in the last couple of years.
SNY has a Gross Margin of 69.08%. This is in the better half of the industry: SNY outperforms 71.51% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% |
OM growth 3Y0.85%
OM growth 5Y2.94%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SNY is creating some value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
SNY has more shares outstanding than it did 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
SNY has an Altman-Z score of 2.95. This is not the best score and indicates that SNY is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.95, SNY is doing good in the industry, outperforming 73.66% of the companies in the same industry.
SNY has a debt to FCF ratio of 5.74. This is a neutral value as SNY would need 5.74 years to pay back of all of its debts.
The Debt to FCF ratio of SNY (5.74) is better than 84.95% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that SNY is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, SNY is in line with its industry, outperforming 43.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 2.95 |
ROIC/WACC1.73
WACC7.15%
2.3 Liquidity
SNY has a Current Ratio of 1.00. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY has a worse Current ratio (1.00) than 84.95% of its industry peers.
SNY has a Quick Ratio of 1.00. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
SNY's Quick ratio of 0.65 is on the low side compared to the rest of the industry. SNY is outperformed by 91.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -1.59% in the last year.
The Earnings Per Share has been growing by 8.19% on average over the past years. This is quite good.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 4.26% in the last year.
Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 5.42% on average per year.
EPS 1Y (TTM)-1.59%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%12.16%
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%12.32%
3.2 Future
Based on estimates for the next years, SNY will show a small growth in Earnings Per Share. The EPS will grow by 6.16% on average per year.
SNY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.09% yearly.
EPS Next Y-4.89%
EPS Next 2Y3.65%
EPS Next 3Y5.55%
EPS Next 5Y6.16%
Revenue Next Year2.85%
Revenue Next 2Y4.55%
Revenue Next 3Y5.01%
Revenue Next 5Y5.09%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.49, SNY is valued correctly.
91.94% of the companies in the same industry are more expensive than SNY, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 28.29. SNY is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 11.51, which indicates a very decent valuation of SNY.
Based on the Price/Forward Earnings ratio, SNY is valued cheaper than 86.02% of the companies in the same industry.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.49 | ||
| Fwd PE | 11.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 93.01% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 82.26% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.36 | ||
| EV/EBITDA | 7 |
4.3 Compensation for Growth
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.52
EPS Next 2Y3.65%
EPS Next 3Y5.55%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.84%, SNY has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 4.09, SNY pays a better dividend. On top of this SNY pays more dividend than 94.62% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.28, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.84% |
5.2 History
The dividend of SNY has a limited annual growth rate of 3.34%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
SNY has decreased its dividend recently.
Dividend Growth(5Y)3.34%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
59.74% of the earnings are spent on dividend by SNY. This is a bit on the high side, but may be sustainable.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP59.74%
EPS Next 2Y3.65%
EPS Next 3Y5.55%
SANOFI-ADR
NASDAQ:SNY (1/21/2025, 5:20:02 PM)
After market: 51.69 0 (0%)51.69
+0.95 (+1.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.52%
Inst Owner Change-0.04%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap129.60B
Analysts78.57
Price Target60.09 (16.25%)
Short Float %0.19%
Short Ratio1.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.84% |
Yearly Dividend3.56
Dividend Growth(5Y)3.34%
DP59.74%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.02%
Min EPS beat(2)2.32%
Max EPS beat(2)3.72%
EPS beat(4)2
Avg EPS beat(4)0.32%
Min EPS beat(4)-2.41%
Max EPS beat(4)3.72%
EPS beat(8)5
Avg EPS beat(8)2.05%
EPS beat(12)9
Avg EPS beat(12)3.25%
EPS beat(16)13
Avg EPS beat(16)3.91%
Revenue beat(2)1
Avg Revenue beat(2)0.68%
Min Revenue beat(2)-0.35%
Max Revenue beat(2)1.71%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)1.71%
Revenue beat(8)3
Avg Revenue beat(8)14.24%
Revenue beat(12)7
Avg Revenue beat(12)28.34%
Revenue beat(16)11
Avg Revenue beat(16)34.58%
PT rev (1m)-0.56%
PT rev (3m)-5.56%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)-1.37%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.42%
Revenue NY rev (1m)-2.23%
Revenue NY rev (3m)-3.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.49 | ||
| Fwd PE | 11.51 | ||
| P/S | 1.76 | ||
| P/FCF | 30.36 | ||
| P/OCF | 15.48 | ||
| P/B | 1.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7 |
EPS(TTM)4.14
EY8.01%
EPS(NY)4.49
Fwd EY8.69%
FCF(TTM)1.7
FCFY3.29%
OCF(TTM)3.34
OCFY6.46%
SpS29.3
BVpS29.91
TBVpS-1.66
PEG (NY)N/A
PEG (5Y)1.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROCE | 15.65% | ||
| ROIC | 12.36% | ||
| ROICexc | 13.27% | ||
| ROICexgc | 75.28% | ||
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% | ||
| FCFM | 5.81% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.23%
ROIC(5y)6.72%
ROICexc(3y)8.13%
ROICexc(5y)7.63%
ROICexgc(3y)39.23%
ROICexgc(5y)35.01%
ROCE(3y)9.15%
ROCE(5y)8.51%
ROICexcg growth 3Y4.96%
ROICexcg growth 5Y9.87%
ROICexc growth 3Y3.21%
ROICexc growth 5Y7.01%
OM growth 3Y0.85%
OM growth 5Y2.94%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
F-Score5
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Debt/EBITDA | 0.72 | ||
| Cap/Depr | 90.48% | ||
| Cap/Sales | 5.59% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.58% | ||
| Profit Quality | 52.55% | ||
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | 2.95 |
F-Score5
WACC7.15%
ROIC/WACC1.73
Cap/Depr(3y)62.81%
Cap/Depr(5y)53.83%
Cap/Sales(3y)5.53%
Cap/Sales(5y)5.38%
Profit Quality(3y)123.22%
Profit Quality(5y)125.66%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.59%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%12.16%
EPS Next Y-4.89%
EPS Next 2Y3.65%
EPS Next 3Y5.55%
EPS Next 5Y6.16%
Revenue 1Y (TTM)4.26%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%12.32%
Revenue Next Year2.85%
Revenue Next 2Y4.55%
Revenue Next 3Y5.01%
Revenue Next 5Y5.09%
EBIT growth 1Y-19.82%
EBIT growth 3Y8.43%
EBIT growth 5Y8.52%
EBIT Next Year16.18%
EBIT Next 3Y11.74%
EBIT Next 5Y7.45%
FCF growth 1Y-45.51%
FCF growth 3Y10.68%
FCF growth 5Y15.17%
OCF growth 1Y-15.61%
OCF growth 3Y11.41%
OCF growth 5Y13.08%